Verma Abhimanyu 4/A

What Happened
Abhimanyu Verma, Chief Technology Officer of SOPHiA GENETICS (SOPH), was granted equity on April 2, 2026. The Form 4/A reports two award entries: 82,136 ordinary shares acquired at $0.00 and 119,760 derivative awards (RSUs) acquired at $0.00, for a combined 201,896 share-based awards. The transaction is an award/grant (code A) and involved no cash payment.

Key Details

• Transaction date: April 2, 2026 (reported on an amended Form 4 filed April 8, 2026).
• Awards reported:
  • 82,136 ordinary shares @ $0.00 (acquired)
  • 119,760 derivative awards (RSUs) @ $0.00 (acquired)
• Total awarded on 4/2/2026: 201,896 share equivalents.
• Shares beneficially owned following the transaction (corrected): 207,949 ordinary shares (per footnote F2; this Form 4/A corrects the Column 5 amount previously reported).
• Vesting/terms:
  • F1: RSU grant — 25% vests April 2, 2027; remaining 75% vest in equal quarterly installments through April 2, 2030.
  • F3: (separate note in filing) indicates a share option vests 25% April 2, 2027 then in equal monthly installments through April 2, 2030.
• Filing notes: This is an amended Form 4 (filed 2026-04-08) amending the Form 4 filed 2026-04-03 to correct beneficial ownership. No tax-withholding or 10b5-1 plan is indicated on the form.

Context
These entries are grants/awards (not purchases or open-market sales) and therefore reflect compensation/equity incentives subject to multi-year vesting schedules. Derivative RSUs represent contingent rights to receive ordinary shares upon vesting — not immediate marketable shares. The amendment corrects the ownership total but does not change that the awards were granted at $0.00.